Axsome Therapeutics Reports Q1 2025 Earnings with Strong Revenue Growth

Axsome (AXSM) reported a year-over-year total revenue growth of 62% in the first quarter, driven by strong demand for its products Auvelity and Sunosi. The company also highlighted recent FDA approval of Symbravo as well as progress on three NDA-stage product candidates.

By Motley Fool Transcribing, The Motley Fool May 4, 2026 39 min read · Yahoo Finance · May 4, 2026, 15:35 UTC

Axsome Therapeutics Reports Q1 2025 Earnings with Strong Revenue Growth

Tickers: $AXSM

Topics: CNS drugs FDA approval pharmaceuticals revenue growth

Read the full article at Yahoo Finance

More World news

Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC